Lantheus Holdings, Lantheus Medical Imaging and Lantheus Alpha Therapy now beneficially own 10.0% of Perspective Therapeutics, or 11,440,513 shares, after dilution and share dispositions. The activist 13D position matters to investors because the group is authorized to sell its Common Stock from time to time, subject to certain market conditions.
Key Highlights
- Lantheus Alpha sold 78,145 shares on August 31, 2026, 35,769 on September 1, 2026, 42,129 on September 2, 2026 and 80,783 on September 3, 2026.
- Lantheus Alpha is authorized to sell Common Stock through several transaction types, subject to certain market conditions.
- Lantheus Holdings, Lantheus Medical Imaging and Lantheus Alpha Therapy each beneficially own 11,440,513 Perspective Therapeutics shares.
- The Lantheus group holds 10.0% of Perspective Therapeutics’ Common Stock as of September 3, 2026.
Perspective Therapeutics, Inc. (AMEX: CATX) now has Lantheus Holdings, Lantheus Medical Imaging and Lantheus Alpha Therapy holding 10.0% of its Common Stock, or 11,440,513 shares. The activist 13D position fell after dilution and dispositions of Perspective Therapeutics shares. The ownership information is reported as of September 3, 2026.
Lantheus Group Holds 10%
Lantheus Holdings, Inc (NASDAQ: LNTH). Lantheus Medical Imaging, Inc. and Lantheus Alpha Therapy, LLC each beneficially own the same aggregate position in Perspective Therapeutics. Each of the three Lantheus entities may be deemed to share voting and dispositive power over the Common Stock held by Lantheus Alpha. The disclosed share count has been adjusted for the company’s 1-for-10 reverse stock split.
Lantheus Alpha sold 78,145 shares on August 31, 2026, at an average price of $3.143 per share. It sold another 35,769 shares on September 1, 2026, at an average price of $3.1193 per share. The sales continued with 42,129 shares on September 2, 2026, at an average price of $3.1147 per share, followed by 80,783 shares on September 3, 2026, at an average price of $3.1058 per share. The transactions were identified as dispositions by the Reporting Persons.
Sales Authorized Under Conditions
The Lantheus entities are authorized to sell Perspective Therapeutics Common Stock from time to time, subject to certain market conditions. Lantheus Alpha’s principal Business is entering into transactions contemplated by the Investment Agreement.



Please wait processing your request...